Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
Completed
Hoffmann-La Roche
Phase 2
2009-01-01
The purpose of this trial is to determine if rash caused by erlotinib can be successfully
treated and if so to determine the optimal treatment approach.
Hypothesis:
Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy
with minocycline can prevent occurrence in 50% of these patients.
Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80%
of patients.
Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of
patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring
treatment with monotherapy intervention.
Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
Completed
British Columbia Cancer Agency
Phase 2
2009-01-01
The purpose of this trial is to determine if rash caused by erlotinib can be successfully
treated and if so to determine the optimal treatment approach.
Hypothesis:
Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy
with minocycline can prevent occurrence in 50% of these patients.
Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80%
of patients.
Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of
patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring
treatment with monotherapy intervention.
Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
Withdrawn
National Cancer Institute (NCI)
Phase 1/Phase 2
1969-12-31
The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and
minocycline when given alone or in combination to learn which is better for controlling
symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
